Objectives: To describe the prevalence of transmitted drug resistance (TDR) among 84 children newly diagnosed with HIV in France in 2006-17.
Introduction
Although currently recommended universal maternal and infant antiretroviral prophylaxis has dramatically reduced the risk and number of infant HIV infections, 160 000 new paediatric infections occur each year, mainly in low-and middle-income countries (LMICs) (http://www.who.int/hiv/data). In these countries, the transmission of resistant viruses to infants has become more common. 1 In high-income countries, where the rate of HIV mother-tochild transmission (MTCT) is less than 1%, new cases of HIV infection continue to be diagnosed in children whose mothers were not tested for HIV or who seroconverted during pregnancy, and in immigrant children arriving from highly HIV-prevalent areas. 2 Monitoring of transmitted drug resistance (TDR) in children is required to optimize treatment success and preserve future therapeutic options. However, recent data about TDR prevalence in children newly diagnosed with HIV in high-income countries still remain limited. [3] [4] [5] Moreover, few data have been published about the prevalence of resistance to second-generation NNRTIs and integrase inhibitors (INIs), which can now be used in the paediatric population. The present work aimed to evaluate the prevalence of TDR in children newly diagnosed with HIV-1 in France between 2006 and 2017 and referred to Necker Hospital (Paris).
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Patients and methods

Ethics
This research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Parents/guardians provided informed consent for the anonymous use of their children's clinical and biological data for biomedical research at the time of data collection.
Study population
The study population comprised 84 children and adolescents newly diagnosed with HIV-1 in France between 2006 and 2017 and referred to Necker hospital.
Genotypic resistance analysis
Genotypic resistance tests were performed on plasma samples collected before initiation of combined ART (cART). Reverse transcriptase, protease and integrase genes were amplified and sequenced. In INI-naive patients with virological suppression who had not previously undergone integrase gene sequencing, resistance to INIs was evaluated by sequencing the integrase gene from PBMC-associated HIV-1 DNA. Genotypic resistance tests were performed using either commercial assays [TrueGene HIV-1 genotyping kit (Siemens Healthcare, Eragny, France), Viroseq sequencing-based HIV-1 genotyping kit (Abbott, Rungis, France)] or using the consensus technique of the French National Agency for AIDS Research (ANRS) Resistance study group (www.hivfrenchresistance.org).
HIV-1 resistance-associated mutations (RAMs) were defined using both the 2009 Stanford RAM list 6 for NRTIs, first-generation NNRTIs and PIs and the 2017 French ANRS algorithm v27 (www.hivfrenchresistance.org) for etravirine, rilpivirine and INIs. The ANRS algorithm includes all the rilpivirine-, etravirine-and INI-related RAMs reported in the 2017 IAS-USA resistance mutations list. 7 The studied RAMs were: (i) resistance to PIs: , E138A/K/T, G140A/C/S, Y143A/C/G/ H/R/S, P145S, S147G, Q148E/G/H/K/R, V151L, S153F/Y, N155H/S/T, E157Q, S230G/R and R263K. Mutations defining doravirine resistance were V106A, V106M, V108I, H221Y, F227L, F227C, F227V, M230I, L234I and P236L. 8 For estimating the genotypic susceptibility score (GSS), each drug, except ritonavir, was scored as 1 or 0 in the case of 'susceptibility' or 'intermediate/high resistance', respectively, according to the ANRS interpretation algorithm. For each of the first-line recommended cART combinations in French guidelines, 9 the arithmetic sum of the individual scores for the specific drugs provided the total treatment-related GSS.
Phylogenetic analysis
The HIV-1 subtype was determined by phylogenetic analysis of reverse transcriptase sequences, as previously described. 10 
Results
Study population
Overall, 84 patients were included in our study (Table 1) . Children were mainly infected through MTCT (73/84; 86.9%), but only 18 patients (24.7% of vertically infected children) were previously exposed to antiretroviral prophylaxis from MTCT. Around one-third of patients were diagnosed late in their disease: the proportion of those with CDC stage C disease and CD4 cell count ,15% was 25.7% in 2006-09, 22.9% in 2010-13 and 42.1% in 2014-17.
HIV-1 diversity
Subtype B strains were isolated in eight patients (9.5%) ( Table 1 ). All but one of the subtype B-infected children were born in France to a mother who originated from France or north-west Africa. The viral diversity was high: 90.5% of strains clustered with non-B subtypes, mainly CRF02_AG (42.1% of non-B subtypes).
TDR
RAMs in the reverse transcriptase and/or protease genes were identified in 7 strains (8.3%) using the 2009 Stanford list and in 14 strains (16.7%) using both the Stanford list and the 2017 French ANRS algorithm ( Table 1 ). The prevalence of PI-, NRTI-, firstgeneration NNRTI-and second-generation NNRTI-associated RAMs was 0%, 3.6%, 6.0% and 11.9%, respectively (global prevalence of NNRTI-associated RAMs " 14.3%). Viruses with single-, dual-and triple-class resistance were isolated in 15.5%, 1.2% and 0%, respectively ( Table 2 ). The strain with dual-class resistance was isolated in a child infected through blood transfusion in Angola. Additionally, 3/60 (5.0%) strains, belonging to CRF02_AG, had INI-related RAMs (E157Q mutation in all cases).
RAMs were identified in 1/18 (5.6%) children exposed to antiretroviral-based MTCT prophylaxis.
Overall, the prevalence of TDR related to the most commonly prescribed PIs, NRTIs and INIs was very low: 1.2% to lamivudine/ emtricitabine, abacavir and tenofovir; 2.4% to zidovudine; and 5.0% to raltegravir, elvitegravir and dolutegravir. None of them were resistant to lopinavir, atazanavir and darunavir. These results contrast with the prevalence of first-and second-generation NNRTI-related TDR: 6.0%, 9.5% and 10.5% of strains were resistant to efavirenz/nevirapine, etravirine and rilpivirine, respectively. Finally, the prevalence of strains resistant to doravirine and cabotegravir was very low (2.4% and 0%, respectively).
Impact of TDR on first-line strategies
The proportion of fully active (GSS " 3) regimens was 98.8% for abacavir/lamivudine (or tenofovir/emtricitabine) plus darunavir/ritonavir (or atazanavir/ritonavir or lopinavir/ritonavir), 97.6% for zidovudine/ lamivudine plus darunavir/ritonavir (or atazanavir/ritonavir or lopinavir/ritonavir), 95.2% for abacavir/lamivudine (or tenofovir/emtricitabine) plus raltegravir (or elvitegravir/cobicistat or dolutegravir), 94.1% for zidovudine/lamivudine plus raltegravir (or elvitegravir/ cobicistat or dolutegravir), 94.1% for abacavir/lamivudine (or tenofovir/emtricitabine) plus efavirenz (or nevirapine), 92.9% for zidovudine/lamivudine plus efavirenz (or nevirapine) and 89.3% for abacavir/lamivudine (or tenofovir/emtricitabine) plus rilpivirine.
Impact of TDR on future antiretroviral strategies
The proportions of fully active combinations were 96.4% for abacavir/lamivudine (or tenofovir/emtricitabine) plus doravirine and 89.3% for rilpivirine/cabotegravir.
Frange et al. 
JAC
Discussion
We herein report one of the largest recent studies of TDR in children newly diagnosed with HIV-1 in high-income countries. The prevalence of TDR (8.3%) was similar to the prevalences recently reported in Germany 3 and in the USA 4 but lower than the prevalences observed in Brazil, 11, 12 Spain 5 and sub-Saharan African countries. 1, 13 Several factors could explain these differences. First, the rate of MTCT is less than 1% in France, where most of the pregnant women diagnosed with HIV are successfully treated with antiretrovirals.
14 Thus, most of the new cases of paediatric HIV infection (78.6% in our study) are diagnosed in children who are unexposed to antiretroviral prophylaxis, i.e. patients whose mothers were not tested for HIV or who seroconverted during pregnancy.
2 Second, because .80% of pregnant women diagnosed with HIV and followed up in France receive a PI-based combination, 14 the proportion of children exposed to NNRTI during prevention of mother-tochild transmission is low (7.1% in our study). Third, because French guidelines discourage HIV-positive women from breastfeeding, the proportion of newborns exposed to antiretrovirals through breastfeeding is very low. Consequently, the TDR observed in the 11 vertically infected children unexposed to antiretroviral-based prophylaxis of MTCT is probably due to transmission of resistant strains from their antiretroviral-naive mothers and/or to transmission of viruses with polymorphic mutations. The situation is highly different in LMICs, where resistant strains are frequently transmitted during pregnancy or breastfeeding from women experiencing treatment failure (usually NNRTI-containing regimens), or could be selected for by the selection of RAMs in infants who are infected despite neonatal antiretroviral prophylaxis (most commonly nevirapine). 1, 13 This could explain the lower paediatric TDR prevalence observed in France (not only NNRTI-related but also NRTI-related TDR) than in LMICs.
Continuous monitoring of TDR is required given the potential impact on the recommended first-line therapies. Because of the higher prevalence of first-and second-generation NNRTI-related TDR (due in part to polymorphic mutations) compared with PI-related TDR, our results suggest that the preferential choice of PI-over NNRTI-based combinations to treat recently diagnosed children be implemented, as the risk of early failure will be reduced. We also described INI-related TDR, which has been rarely studied in previous paediatric studies, because several INIs are now available for use in infants and children. The E157Q polymorphic mutation in the integrase gene has been considered to be conferring resistance to raltegravir, elvitegravir and once-daily dolutegravir (and intermediate resistance to twice-daily dolutegravir), according to the 2017 ANRS algorithm. However, recent data suggest that the susceptibility to dolutegravir could be less affected by this substitution than the susceptibility to raltegravir and elvitegravir. 15 Thus, in newly diagnosed children with an isolated E157Q Frange et al. mutation or without available results of genotypic resistance testing, these data and our results suggest the preferential choice of dolutegravir rather than raltegravir or elvitegravir.
Our results support current guidelines to perform genotypic resistance testing in all HIV paediatric new diagnoses, even if cART is not initiated immediately. 9 These results could guide the choice of first-line fully active drug combinations but also the discussion of future therapeutic options, including those containing drugs which are not yet available to treat the youngest children.
To sum up, we suggest that, even in the absence of previous exposure to antiretroviral MTCT prophylaxis, the preferential choice of PI-or dolutegravir-over NNRTI-based combinations to treat newly diagnosed children be implemented. Continuous monitoring of TDR should continue, given the potential impact on the recommended first-line therapies. Importantly, monitoring of the prevalence of INI-related RAMs will also be key, given the expanding role of these medications in both pregnant women and children.
